Hims & Hers Health (NYSE:HIMS) Downgraded to “Strong Sell” Rating by Zacks Research

Hims & Hers Health (NYSE:HIMS) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. UBS Group set a $32.00 price target on Hims & Hers Health in a report on Tuesday, November 4th. Evercore ISI started coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective for the company. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a report on Monday, January 5th. Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, KeyCorp assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $44.54.

Hims & Hers Health Price Performance

HIMS opened at $30.44 on Monday. The company has a market capitalization of $6.93 billion, a P/E ratio of 56.37, a PEG ratio of 5.32 and a beta of 2.37. The company has a 50-day moving average of $35.41 and a 200-day moving average of $45.43. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health has a 1-year low of $23.97 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 EPS. Equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a stock buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 125,544 shares of company stock valued at $4,620,821. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the 1st quarter worth about $30,000. Parallel Advisors LLC lifted its stake in shares of Hims & Hers Health by 175.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,155 shares of the company’s stock worth $58,000 after acquiring an additional 735 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Hims & Hers Health by 24.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 15,638 shares of the company’s stock worth $750,000 after acquiring an additional 3,050 shares during the period. Finally, UMB Bank n.a. boosted its holdings in shares of Hims & Hers Health by 87.3% in the second quarter. UMB Bank n.a. now owns 2,453 shares of the company’s stock valued at $122,000 after acquiring an additional 1,143 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.